SFDA-2023-0097-V497

Type IB variation for application SFDA-2023-0097. Type IB variation: Labeling Change for Thymosilib — major revision

Variation Number
SFDA-2023-0097-V497
Type
Type IB
Application
SFDA-2023-0097
Change
CHG-2024-0197
Status
Overdue
Fee
€2,440
Submitted
2024-04-09
Approved
—
Description

Type IB variation: Labeling Change for Thymosilib — major revision